A BB cream is two products in one tube, and regulators read it as both. The pigment side behaves like makeup. The claim side — barrier support, brightening, wrinkle improvement, sun protection — sits in territory where the manufacturer has to show its work.
That split is where most compliance failures in this category begin. Rarely with a banned ingredient. Usually with a sentence on the carton that the formula file cannot support.
Two products in one tube
The format started in 1980s Germany as a post-procedure balm and was rebuilt in Korea in the early 2000s into something people would wear every day. Korean formulators pushed it toward light coverage plus treatment actives, and that hybrid is what exported.
The commercial logic is obvious — one step instead of three. The regulatory consequence is less obvious to brands entering the category for the first time. Every treatment benefit added to justify the skincare half is a claim, and claims carry evidence requirements that a plain tinted moisturiser never had to meet.
Korean brands have carried the format into Turkey and across Southeast Asia, and the claim vocabulary travels with it. It doesn’t always survive the trip. Copy that reads as ordinary marketing in one market is a functional-cosmetic claim requiring registered evidence in another. Brands working through Korean import documentation usually meet this the first time a distributor asks for the substantiation pack.
The claims regulators actually read
Whitening and wrinkle improvement draw attention most reliably. Both are efficacy claims about skin function, both invite a demand for test data, and both turn up on BB cream packaging almost by default, because the category grew up promising them.
Sun protection is the third. An SPF figure is a measured value from a defined test protocol, not a formulation estimate, and it has to be earned on the finished product rather than inherited from a filter supplier’s datasheet.
The pattern across enforcement cases is consistent. Labelling and advertising, rather than ingredient safety, is where cosmetic products get caught. Ingredient compliance is a checkable list against an annex. Claim compliance is a judgement about whether the evidence behind a sentence holds, which is a far easier thing to get wrong quietly and expensively.
Digital channels widened the exposure
Packaging copy goes through review. Influencer scripts often don’t. A brand that carefully wrote “helps improve the look of uneven tone” on the carton can still end up with a paid creator saying “it whitened my skin in a week” — and in most jurisdictions the brand owns that sentence.
Reach makes it worse. An unreviewed claim in a thirty-second video will outrun the compliant version on the box by a wide margin. Indonesia’s action against misleading BB cream advertising covered exactly this ground, and it was never limited to what was printed on the tube.
For an OEM/ODM partner, the practical fix is boring and effective: issue the brand a claim sheet listing what the finished formula can and cannot be said to do, in plain language, and treat that sheet as the boundary for every channel including creator briefs.
What the category looks like now
Two shifts matter if you’re specifying this format for production.
- Shade range. Early formulations shipped in one or two universal tones, which quietly capped the addressable market. Current lines carry natural-looking shade sets, which lets the product sit alongside a foundation instead of competing with it.
- Segment expansion. Men’s lines, and lines built around a specific concern, are now routine briefs rather than experiments. That changes the pigment work, the texture target and the claim set all at once.
Shoppers read ingredient lists in a way they didn’t ten years ago, and they compare what the list implies against what the front of the pack promises. Formulations built around serum and ampoule actives, hyaluronic acid among them, are standard now. That is defensible when the inclusion level does something measurable and awkward when it exists to be printed.
Younger buyers in particular treat the product as a skin-management tool rather than a cosmetic, which raises the bar on texture and finish as much as on claims.
Build the file before the campaign
The sequence that saves money is unglamorous. Fix the claim set with the manufacturer while the formula is still open, commission the testing each claim requires, then write the campaign against what comes back. Reversing that order is how brands end up pulling artwork or defending a promise the lab never supported.
Markets disagree about which claims need what evidence, so a single global claim set is usually a fiction. A brand shipping into Indonesia’s ingredient and notification regime and into Korea at the same time will need two versions of the same sentence. Planning for that is cheaper than discovering it at artwork sign-off.
“Compliance headlines get a brand’s attention fast, and understandably so — nobody wants their product used as the example. What we tell clients in practice is that the safest long-term marketing strategy is also the simplest: don’t promise more than the formula can honestly support, especially around whitening or wrinkle-improvement claims, which regulators are clearly scrutinizing closely right now. In client conversations, we’re also seeing more brands ask us to build a documented paper trail behind every claim on the label before a campaign goes live, rather than after, because retroactively defending a claim is far more expensive — in both money and trust — than getting it right from the start.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS